
Appeals Court Revives $6.7 Billion Lawsuit Against Bristol Myers
A federal appeals court has reinstated a $6.7 billion lawsuit alleging that Bristol Myers Squibb deliberately stalled federal approvals for three specific drugs to avoid paying former Celgene shareholders. The 2nd U.S. Circuit Court of Appeals ruled that a lower court judge erred in previously dismissing the case.
















